PMID- 34163200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 14
DP  - 2021
TI  - Influence of Low Total Triiodothyronine Levels on Bone Turnover Markers in Type 2 
      Diabetes Mellitus.
PG  - 2727-2733
LID - 10.2147/DMSO.S309079 [doi]
AB  - PURPOSE: The aim of this study was to investigate whether low total 
      triiodothyronine (TT3) could affect bone turnover in patients with type 2 
      diabetes mellitus (T2DM). MATERIALS AND METHODS: This is a cross-sectional study 
      that recruited 577 patients with T2DM, 141 patients formed the low TT3 group 
      (TT3<1.30nmol/L) and 436 patients formed the control group (TT3>/=1.30nmol/L), and 
      the low TT3 group was further subdivided into four groups based on the TT3 level. 
      To investigate whether TT3 level is associated with poor glycemic control, all 
      participants were divided into high glycosylated hemoglobin (HbA1c) group and low 
      HbA1c group using HbA1c 10.5% as the boundary. RESULTS: The levels of OC and PINP 
      were significantly lower in the low TT3 group compared with the control group (P 
      < 0.05). TT3 positively correlated with OC and PINP (r = 0.219, P = 0.009; r = 
      0.208, P = 0.019) in the low TT3 group, and this positive correlation still 
      existed after adjusting for other factors in multilinear regression analysis. 
      Next, we want to find a cut-off point to prevent osteoporosis, we divided the 
      patients in the low TT3 group into four groups based on the TT3 level, the levels 
      of OC and PINP were significantly lower in the TT3 < 1.00 nmol/L group than in 
      the TT3 >/= 1.00 nmol/L groups. CONCLUSION: In patients with T2DM, low TT3 levels 
      are associated with impaired bone formation. What's more, bone formation was 
      significantly impaired when TT3 was <1.00 nmol/L.
CI  - (c) 2021 Li et al.
FAU - Li, Zelin
AU  - Li Z
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Yu, Xian
AU  - Yu X
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Ren, Luping
AU  - Ren L
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Wang, Zi
AU  - Wang Z
AD  - Department of Infectious Diseases, Shanghai Fourth People' s Hospital, Shanghai, 
      People's Republic of China.
FAU - Wang, Fei
AU  - Wang F
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Jia, Yujiao
AU  - Jia Y
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Chen, Shuchun
AU  - Chen S
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei, People's 
      Republic of China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
AD  - Hebei Key Laboratory of Metabolic Diseases, Shijiazhuang, Hebei, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210616
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8215934
OTO - NOTNLM
OT  - bone turnover markers
OT  - low TT3 level
OT  - thyroid hormones
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/06/25 06:00
MHDA- 2021/06/25 06:01
PMCR- 2021/06/16
CRDT- 2021/06/24 06:30
PHST- 2021/03/01 00:00 [received]
PHST- 2021/05/11 00:00 [accepted]
PHST- 2021/06/24 06:30 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/06/25 06:01 [medline]
PHST- 2021/06/16 00:00 [pmc-release]
AID - 309079 [pii]
AID - 10.2147/DMSO.S309079 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2021 Jun 16;14:2727-2733. doi: 10.2147/DMSO.S309079. 
      eCollection 2021.